Vitamin K2 immunosuppressive effect on pediatric patients with atopic dermatitis. - GreenMedInfo Summary
Vitamin Kimmunosuppressive effect on pediatric patients with atopic dermatitis.
Pediatr Int. 2019 Dec ;61(12):1188-1195. Epub 2019 Dec 13. PMID: 31560147
BACKGROUND: Over 20 kinds of steroids, tacrolimus ointments, and cyclosporine capsules are usually recommended for the treatment of atopic dermatitis (AD), depending on the symptoms of patients. However, several side effects sometimes occur with the extensive use of these agents for the treatment of pediatric AD patients. The purpose of this study was to explore whether vitamin Kcould be a new immunosuppressive candidate for pediatric patients with AD.
METHODS: The immunosuppressive efficacy of vitamin Kwas evaluated through a cell-culture procedure using mitogen-activated peripheral blood mononuclear cells (PBMCs) obtained from pediatric AD patients.
RESULTS: The mean (SD) ICvalue of vitamin Kfor the proliferation of concanavalin A-activated PBMCs was 15.37 (30.05) μmol/L, while the value for tacrolimus was 0.10 (0.28) ng/mL (0.12 (0.35) nmol/L). There was a significant correlation between the ICvalues for vitamin Kand those for tacrolimus (P = 0.0001, r = 0.8871). However, there was no significant correlation between the ICvalues of vitamin Kand those of cyclosporine A or methylprednisolone. A significant correlation between the ICvalues of vitamin Kor tacrolimus and blood eosinophil counts (P = 0.0099, r = 0.7086 and P = 0.0032, r = 0.7722, respectively) was observed.
CONCLUSION: Vitamin K-inhibited T-cell mitogen stimulated proliferation of PBMCs from pediatric AD patients in a dose-dependent manner. The PBMCs from pediatric AD patients were more sensitive to the immunosuppressive efficacy of vitamin Kthan the PBMCs from healthy subjects. The individual immunosuppressive pharmacological efficacy of vitamin Kand of tacrolimus could be inferred from the blood eosinophil count of pediatric AD patients.